ALA · ASX

Arovella Therapeutics Limited (ASX:ALA)

AU$0.095

 -0.005 (-5.0%)
ASX:Live
01/07/2025 04:10:20 PM
HALO Ords HALO Consensus Value GROWTH AUS Big Candle All-Consensus +1
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

ALA Overview

ALA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ALA

Website

N/A

Telephone

Address

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$130.39M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.21

Trade Value (12mth)

AU$54,778.00

1 week

0%

1 month

31.58%

YTD

-41.18%

1 year

-31.03%

All time high

14.78

Key Fundamentals

EPS 3 yr Growth

-38.80%

EBITDA Margin

%

Operating Cashflow

-$7m

Free Cash Flow Return

-92.10%

ROIC

-116.60%

Interest Coverage

-1,247.60

Quick Ratio

6.40

Other Data

Shares on Issue (Fully Dilluted)

1054m

HALO Sector

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date Announcements

30 June 25

Retirement of Non-Executive Chairman

×

Retirement of Non-Executive Chairman

30 June 25

Notice Under Section 708A

×

Notice Under Section 708A

27 June 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

24 June 25

Notice Under Section 708A

×

Notice Under Section 708A

23 June 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

17 June 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

17 June 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

17 June 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

17 June 25

Notification of cessation of securities - ALA

×

Notification of cessation of securities - ALA

17 June 25

Notification of cessation of securities - ALA

×

Notification of cessation of securities - ALA

17 June 25

Notification of cessation of securities - ALA

×

Notification of cessation of securities - ALA

17 June 25

Notice Under Section 708A

×

Notice Under Section 708A

08 May 25

Results of Extraordinary General Meeting

×

Results of Extraordinary General Meeting

05 May 25

ALA exclusive iNKT technology option with Baylor

×

ALA exclusive iNKT technology option with Baylor

29 April 25

Investor webinar presentation

×

Investor webinar presentation

24 April 25

Notification regarding unquoted securities - ALA

×

Notification regarding unquoted securities - ALA

16 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 April 25

Quarterly Update Webinar

×

Quarterly Update Webinar

10 April 25

Notice of Extraordinary General Meeting/Proxy Form

×

Notice of Extraordinary General Meeting/Proxy Form

01 April 25

Cancel - Proposed issue of securities - ALA

×

Cancel - Proposed issue of securities - ALA

01 April 25

Cancel - Proposed issue of securities - ALA

×

Cancel - Proposed issue of securities - ALA

27 March 25

Notification of cessation of securities - ALA

×

Notification of cessation of securities - ALA

26 March 25

Prospectus

×

Prospectus

26 March 25

Proposed issue of securities - ALA

×

Proposed issue of securities - ALA

26 March 25

Application for quotation of securities - ALA

×

Application for quotation of securities - ALA

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.095.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.21.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.07.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .
The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.095.
The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.21.
The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.07.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.
Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.
Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.
The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .